Risultati per: Nuovo farmaco per la malattia di Crohn e colite ulcerosa

Questo è quello che abbiamo trovato per te

Healthy first-degree relatives from multiplex families versus simplex families have a higher subclinical intestinal inflammation, a distinct fecal microbial signature, and harbor a higher risk of developing Crohn’s disease

Gastroenteology

Unaffected first-degree relatives (FDRs) from families with two or more affected FDRs with Crohn’s disease (CD, multiplex families) have a high risk of developing CD, although the underlying mechanisms driving this risk are poorly understood. We aimed to identify differences in biomarkers between FDRs from multiplex versus simplex families and to investigate the risk of future CD onset accounting for potential confounders.

Leggi →
Settembre 2024

Crohn’s patients and healthy infants share immunodominant B cell response to commensal flagellin peptide epitopes

Gastroenteology

Inflammatory bowel disease is a chronic manifestation of dysregulated immune response to the gut microbiota in genetically pre-disposed hosts. Nearly half of patients with Crohn’s disease (CD) develop selective serum IgG response to flagellin proteins expressed by bacteria in the Lachnospiraceae family. This study aimed to identify the binding epitopes of these IgG antibodies and assess their relevance in CD and in homeostasis.

Leggi →
Agosto 2024
← Pagina precedente
Pagina successiva →